The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy

Journal of Clinical Neuroscience

Volumn 22, Issue 12, 2015, Pages 1964-1968

  Zhai, Lijie ^a   Dey, Mahua ^b   Lauing, Kristen L ^a   Gritsina, Galina ^a   Kaur, Rajwant ^a   Lukas, Rimas V ^b   Nicholas, M Kelly ^c   Rademaker, Alfred W ^a   Dostal, Carlos R ^d   McCusker, Robert H ^d   Raizer, Jeffrey J ^a   Parsa, Andrew T ^a   Bloch, Orin ^a   Wainwright, Derek A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Brain tumor; Diagnostic; Glioblastoma multiforme; Immunosuppression; Kynurenine; Metabolism; Tryptophan

Indexed keywords

BIOLOGICAL MARKER; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; VITESPEN; TUMOR MARKER;

AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; KIDNEY METASTASIS; LUNG METASTASIS; MELANOMA METASTASIS; MENINGIOMA; NEURILEMOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN METASTASIS; ADULT; AGED; BLOOD; FEMALE; IMMUNOTHERAPY; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; KYNURENINE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 84948713309     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2015.06.018     Document Type: Article

References (27)

1. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
3. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
4. O. Bloch, C.A. Crane, Y. Fuks, and et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial Neuro Oncol 16 2014 274 279
5. J. Schuster, R.K. Lai, L.D. Recht, and et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study Neuro Oncol 17 2015 854 861
6. J.L. Lasky 3rd, E.H. Panosyan, A. Plant, and et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas Anticancer Res 33 2013 2047 2056
7. R.G. Everson, R.M. Jin, X. Wang, and et al. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients J Immunotherap Cancer 2 2014 10
8. D.A. Wainwright, I.V. Balyasnikova, A.L. Chang, and et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Clin Cancer Res 18 2012 6110 6121
9. K. Mitsuka, T. Kawataki, E. Satoh, and et al. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas Neurosurgery. 72 2013 1031 1038 [discussion 1038-9]
10. C.A. Opitz, U.M. Litzenburger, F. Sahm, and et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 478 2011 197 203
11. L. Zhai, K.L. Lauing, A.L. Chang, and et al. The role of IDO in brain tumor immunotherapy J Neurooncol 123 2015 395 403
12. E. Vacchelli, F. Aranda, A. Eggermont, and et al. Trial watch: IDO inhibitors in cancer therapy Oncoimmunology 3 2014 e957994
13. R.J. Boado, J.Y. Li, M. Nagaya, and et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier Proc Natl Acad Sci USA 96 1999 12079 12084
14. S. Fukui, R. Schwarcz, S.I. Rapoport, and et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism J Neurochem 56 1991 2007 2017
15. C.A. Crane, S.J. Han, B. Ahn, and et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein Clin Cancer Res 19 2013 205 214
16. Y. Suzuki, T. Suda, K. Furuhashi, and et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer Lung Cancer 67 2010 361 365
17. M. Huengsberg, J.B. Winer, M. Gompels, and et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients Clin Chem 44 1998 858 862
18. R.A. de Jong, H.W. Nijman, H.M. Boezen, and et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer Int J Gynecol Cancer 21 2011 1320 1327
19. G. Werner-Felmayer, E.R. Werner, D. Fuchs, and et al. Characteristics of interferon induced tryptophan metabolism in human cells in vitro Biochimica Biophys Acta 1012 1989 140 147
20. A.L. Mellor, D. Munn, P. Chandler, and et al. Tryptophan catabolism and T cell responses Adv Exp Med Biol 527 2003 27 35
21. A.L. Mellor, and D.H. Munn Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20 1999 469 473
22. P. Terness, T.M. Bauer, L. Röse, and et al. Inhibition of allogeneic T Cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites J Exp Med 196 2002 447 457
23. J.D. Mezrich, J.H. Fechner, X. Zhang, and et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells J Immunol 185 2010 3190 3198
24. T. Miyazaki, K. Moritake, K. Yamada, and et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation J Neurosurg 111 2009 230 237
25. C. Uyttenhove, L. Pilotte, I. Theate, and et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 2003 1269 1274
26. A.J. Muller, M.D. Sharma, P.R. Chandler, and et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase Proc Natl Acad Sci USA 105 2008 17073 17078
27. S. Adams, C. Teo, K.L. McDonald, and et al. Involvement of the kynurenine pathway in human glioma pathophysiology PLoS ONE 9 2014 e112945